The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
Self-citationStebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., & Pavletich, N. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80203-2 · Cited by 1,364
The complexity of Raf-1 regulation
Morrison, D. K., & Cutler, R. E. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80060-9 · Cited by 635
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.
Bártek, J., Iggo, R. D., Gannon, J., & Lane, D. P. (1990) · PubMed · Cited by 603
Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent
Supko, J. G., Hickman, R. L., Grever, M. R., & Malspeis, L. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00689048 · Cited by 510
Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4
Stepanova, L., Leng, X., Parker, S. B., & Harper, J. W. (1996) · Genes & Development · doi:10.1101/gad.10.12.1491 · Cited by 483 · cited 5×
“The antitumor e ects of GA and other ansamycins likely result from the e ects on four classes of signaling proteins that depend on chaperone action: (1) receptor and nonreceptor protein kinases, such as p185erbB2 [7, 14, 15], EGF-R [17, 18] and v-src [34, 36], (2) serine/threonine kinases such as Raf-1 [23] and CDK4 […”
BackgroundInfluentialGELDANAMYCIN, A NEW ANTIBIOTIC
DEBOER, C., MEULMAN, P. A., WNUK, R. J., & PETERSON, D. H. (1970) · The Journal of Antibiotics · doi:10.7164/antibiotics.23.442 · Cited by 466
Schulte, T. W., Blagosklonny, M. V., Ingui, C., & Neckers, L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.41.24585 · Cited by 456
Self-citationMutant conformation of p53 translated in vitro or in vivo requires functional HSP90.
Blagosklonny, M. V., Toretsky, J., Bohen, S., & Neckers, L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8379 · Cited by 314
Self-citationProgesterone Receptor Structure and Function Altered by Geldanamycin, an hsp90-Binding Agent
Smith, D. F., Whitesell, L., Nair, S. C., Chen, S., Prapapanich, V., & Rimerman, R. A. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6804 · Cited by 289
Schulte, T. W., Blagosklonny, M. V., Romanova, L., Mushinski, J. F., Monia, B. P., Johnston, J. F., Nguyen, P., Trepel, J., & Neckers, L. M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5839 · Cited by 269
Self-citationWhitesell, L. (1996) · Molecular Endocrinology · doi:10.1210/me.10.6.705 · Cited by 263
p185erbB2 Binds to GRP94 in Vivo
Chavany, C., Mimnaugh, E., Miller, P., Bitton, R., Nguyen, P., Trepel, J., Whitesell, L., Schnur, R., Moyer, J. D., & Neckers, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.9.4974 · Cited by 257
Self-citationNucleotides and Two Functional States of hsp90
Sullivan, W., Stensgard, B., Caucutt, G., Bartha, B., McMahon, N., Alnemri, E. S., Litwack, G., & Toft, D. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.12.8007 · Cited by 238
Binding of p23 and hsp90 during assembly with the progesterone receptor.
Johnson, J. L., & Toft, D. O. (1995) · Molecular Endocrinology · doi:10.1210/mend.9.6.8592513 · Cited by 233
Uehara, Y., Hori, M., Takeuchi, T., & Umezawa, H. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.6.2198 · Cited by 233
Interaction of the Rous Sarcoma Virus Protein pp60 src with the Cellular Proteins pp50 and pp90
Brugge, J. S. (1986) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-70810-7_1 · Cited by 224
[31] Use and selectivity of herbimycin A as inhibitor of protein-tyrosine kinases
Uehara, Y., & Fukazawa, H. (1991) · Methods in Enzymology · doi:10.1016/0076-6879(91)01033-x · Cited by 215
Schnur, R. C., Corman, M. L., Gallaschun, R. J., Cooper, B. A., Dee, M. F., Doty, J. L., Muzzi, M. L., Moyer, J. D., & DiOrio, C. I. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00019a010 · Cited by 199
Geldanamycin selectively destabilizes and conformationally alters mutated p53.
Blagosklonny, M. V., Toretsky, J. A., & Neckers, L. (1995) · PubMed · Cited by 178
Self-citationHerbimycin, a new antibiotic produced by a strain of Streptomyces.
OMURA, S., IWAI, Y., TAKAHASHI, Y., SADAKANE, N., NAKAGAWA, A., OIWA, H., HASEGAWA, Y., & IKAI, T. (1979) · The Journal of Antibiotics · doi:10.7164/antibiotics.32.255 · Cited by 174
Inhibition of transforming activity of tyrosine kinase oncogenes by herbimycin A
Uehara, Y., Murakami, Y., Mizuno, S., & Kawalt, S. (1988) · Virology · doi:10.1016/0042-6822(88)90649-6 · Cited by 162
Brugge, J., Yonemoto, W., & Darrow, D. (1983) · Molecular and Cellular Biology · doi:10.1128/mcb.3.1.9 · Cited by 160
Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo
Whitesell, L. J., Sutphin, P. D., An, W. G., Schulte, T. W., Blagosklonny, M. V., & Neckers, L. (1997) · Oncogene · doi:10.1038/sj.onc.1201120 · Cited by 127
Self-citationDepletion of the erbB-2 gene product p185 by benzoquinoid ansamycins.
Miller, P. E., DiOrio, C., Moyer, M. P., Schnur, R. C., Bruskin, A. M., Cullen, W., & Moyer, J. D. (1994) · PubMed · Cited by 113
An, W. G., Schnur, R. C., Neckers, L., & Blagosklonny, M. V. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050626 · Cited by 104
Self-citationOkabe, M., Uehara, Y., Miyagishima, T., Itaya, T., Tanaka, M., Kunieda, Y., Kurosawa, M., & Miyazaki, T. (1992) · Blood · doi:10.1182/blood.v80.5.1330.1330 · Cited by 69
The Raf-1 serine/threonine protein kinase.
Magnuson, N. S., Beck, T. W., Vahidi, H., et al. (1994) · PubMed · Cited by 67
Miller, P. E., Schnur, R. C., Barbacci-Tobin, E. G., Moyer, M. P., & Moyer, J. D. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1847 · Cited by 47
Murakami, Y., Mizuno, S., & Uehara, Y. (1994) · Biochemical Journal · doi:10.1042/bj3010063 · Cited by 38
Murakami, Y., Fukazawa, H., Mizuno, S., & Uehara, Y. (1994) · Biochemical Journal · doi:10.1042/bj3010057 · Cited by 24
Cited by
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,387
Triple-negative breast cancer: therapeutic options
Cleator, S., Heller, W., & Coombes, R. C. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70074-8 · Cited by 882
Natural compounds for cancer treatment and prevention
Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780
Chang, F., Steelman, L. S., Lee, J. T., Shelton, J. G., Navolanic, P. M., Blalock, W. L., Franklin, R. A., & McCubrey, J. A. (2003) · Leukemia · doi:10.1038/sj.leu.2402945 · Cited by 725
The HSP90 Family: Structure, Regulation, Function, and Implications in Health and Disease
Hoter, A., El-Sabban, M. E., & Naim, H. Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092560 · Cited by 693
Metadata
- Authors
- Schulte, T. W., & Neckers, L. M.
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 1998-08-12
- Volume
- 42
- Issue
- 4
- Pages
- 273-279
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2053503219
- Cited by
- 478
- References
- 32
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.